DelNS1-2019-nCoV-RBD-OPT
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Trade namesPneucolin
Other namesDelNS1-nCoV-RBD LAIV[1]
Routes of
administration		Intranasal

DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine candidate developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.[2][3][4]

On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.[5]

References

  1. ↑ "A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19". clinicaltrials.gov. United States National Library of Medicine. 29 April 2021. Retrieved 3 May 2021.
  2. ↑ "China's nasal-spray COVID-19 vaccines undergoing clinical trials: official". Xinhua. 11 June 2021. Retrieved 10 July 2021.
  3. ↑ "A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 7 April 2021. Retrieved 24 March 2021.
  4. ↑ "A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 14 November 2020. Retrieved 24 March 2021.
  5. ↑ "关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知" (in Chinese). National Health Commission. 14 December 2022. Retrieved 14 December 2022.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.